Magnetic resonance imaging pattern in natalizumab‐associated progressive multifocal leukoencephalopathy
- 25 June 2012
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 72 (5) , 779-787
Abstract
Objective: Natalizumab is an effective treatment for patients with multiple sclerosis (MS) that is associated with a risk of progressive multifocal leukoencephalopathy (PML). Recommendations were published in 2006 to improve early diagnosis of PML using magnetic resonance imaging (MRI). However, due to the small number of MS patients initially diagnosed with PML, the imaging criteria could only be derived from PML lesions in patients with human immunodeficiency virus. Therefore, there is an urgent need to assess the MRI characteristics of PML in MS patients to update the existing recommendations.Methods: In this retrospective review, the first 40 natalizumab‐treated MS patients diagnosed with PML in the postmarketing setting were identified, of whom 22 (10 with clinically diagnosed immune reconstitution inflammatory syndrome) fulfilled the inclusion criteria for this study. Magnetic resonance images were analyzed according to predefined criteria by 5 independent readers.Results: The most frequent lesion pattern in early scans from PML patients was that of large (>3 cm, 15 of 18), subcortical (18 of 18), T2 or fluid‐attenuated inversion recovery hyperintense (18 of 18), T1‐hypointense (17 of 18), and diffusion‐hyperintense (15 of 15) lesions, with a sharp border toward the gray matter and an ill‐defined border toward the white matter (18 of 18) on T2‐weighted images. We could detect contrast enhancement in 41% (7 of 17) of the cases on the first scan at clinical presentation.Interpretation: Attention to characteristic MRI patterns, especially the presence of contrast enhancement, and the subcortical location may have utility in screening and early diagnosis of PML in natalizumab‐treated MS patients. ANN NEUROL 2012;72:779–787Keywords
This publication has 20 references indexed in Scilit:
- Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyNeurology, 2011
- Successful Management of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy and Immune Reconstitution Syndrome in a Patient With Multiple SclerosisArchives of Neurology, 2010
- Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesThe Lancet Neurology, 2010
- Progressive Multifocal Leukoencephalopathy after Natalizumab MonotherapyNew England Journal of Medicine, 2009
- Treatment of Progressive Multifocal Leukoencephalopathy Associated with NatalizumabNew England Journal of Medicine, 2009
- Evaluation of Patients Treated with Natalizumab for Progressive Multifocal LeukoencephalopathyNew England Journal of Medicine, 2006
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Progressive Multifocal Leukoencephalopathy in a Patient Treated with NatalizumabNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple SclerosisNew England Journal of Medicine, 2005
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005